Allogeneic transplant for - mutated AML: a focus on inhibitors before, during, and after transplant
FMS-like tyrosine kinase 3 ( FLT3 ) mutations are one of the most frequently encountered genetic alterations in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Several tools are currently available to provide an accurate prognosis for patients with these mutatio...
Main Authors: | Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, Mohamad Mohty, Ali Bazarbachi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-10-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620719882666 |
Similar Items
-
Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
by: Mohamad Mohty, et al.
Published: (2020-05-01) -
Comprehensive Review of AL amyloidosis: some practical recommendations
by: Rama Al Hamed, et al.
Published: (2021-05-01) -
Interleukin-22 in graft-versus-host disease after allogeneic stem cell transplantation
by: BAPTISTE eLAMARTHEE, et al.
Published: (2016-04-01) -
Bridging Strategies to Allogeneic Transplant for Older AML Patients
by: Judith Hecker, et al.
Published: (2018-07-01) -
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
by: Razan Mohty, et al.
Published: (2021-07-01)